Results 231 to 240 of about 9,786 (244)
Some of the next articles are maybe not open access.
Efficacy and safety of deferasirox in myelodysplastic syndromes
Annals of Hematology, 2013Transfusion dependence in myelodysplastic syndrome (MDS) patients may lead to organ damage due to accumulation of non-transferrin-bound iron with consequent increased oxidative stress. Iron chelation has been reported in retrospective studies to improve overall survival in low-risk MDS patients, but this information needs to be validated in prospective
Breccia M, ALIMENA, Giuliana
openaire +4 more sources
The effect of deferasirox on endocrine complications in children with thalassemia
Pediatric Hematology and Oncology, 2020Endocrine system dysfunctions are the significant complications of excessive iron overload in beta thalassemia patients. The aim of this study was to evaluate the long-term effect of chelation with deferasirox on endocrine complications. The study group consisted of children with beta thalassemia who had been evaluated for the growth and pubertal ...
Çulha, Vildan +7 more
openaire +4 more sources
Deferasirox—current knowledge and future challenges
Annals of the New York Academy of Sciences, 2010Since the last Cooley's symposium in 2005, our knowledge and clinical experience with deferasirox had advanced considerably. This has been based on prospective multicenter clinical trials, on a scale hitherto unprecedented for chelation therapy, now totalling over 7,400 patients.
openaire +3 more sources
The Journal of Clinical Pharmacology, 2008
Deferasirox (ICL670) is representative of a new class of tridentate iron chelators, formulated as tablets for dispersion. Deferasirox has exhibited high potency and a clinically manageable safety profile in preclinical models and in an extensive clinical program.
Galanello R +12 more
openaire +5 more sources
Deferasirox (ICL670) is representative of a new class of tridentate iron chelators, formulated as tablets for dispersion. Deferasirox has exhibited high potency and a clinically manageable safety profile in preclinical models and in an extensive clinical program.
Galanello R +12 more
openaire +5 more sources
Role of Pharmacogenetics on Deferasirox AUC and Efficacy
Pharmacogenomics, 2016We evaluated deferasirox pharmacokinetic according to SNPs in genes involved in its metabolism and elimination. Moreover, we defined a plasma area under the curve cut-off value predicting therapy response.Allelic discrimination was performed by real-time PCR.
CUSATO, JESSICA +5 more
openaire +3 more sources
Deferasirox: A comprehensive drug profile
Deferasirox is an iron-chelating drug developed by Novartis company for treatment of diseases accompanied by chronic iron overload; such as β-thalassemia or sickle cell diseases. Owing to its advantages such as high affinity, specificity and wide therapeutic window, it is considered as first line treatment.Mohamed Fawzi, Kabil, Maha, Nasr
openaire +2 more sources
Effect of Deferasirox on Midazolam Pharmacokinetics.
Blood, 2007Abstract Introduction: Deferasirox (Exjade®, ICL670) is an oral iron chelator approved for the treatment of iron overload due to chronic transfusions in more than 80 countries. Deferasirox is mainly eliminated via biliary excretion following glucuronidation.
Caroline Arrowsmith-Bensasson +3 more
openaire +2 more sources
Long-term efficacy and safety of deferasirox
Blood Reviews, 2008Deferasirox is an oral iron chelator, with a long half-life, that can be given once daily, because it provides a 24-hour chelation. Several phase II trials and a pivotal phase III trial have established that, in transfusion-dependent patients with beta-thalassaemia major, deferasirox has a similar efficacy to previously available deferoxamine.
openaire +4 more sources
Deferasirox Decreases Busulfan Clearance
Annals of Pharmacotherapy, 2018Ulrich A. Duffner +2 more
openaire +2 more sources